Eoin Maurice Kelleher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eoin Maurice Kelleher has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Anushka Irani
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Division of Rheumatology, Mayo Clinic Florida, Jacksonville, FL, USA
13 shared publicationsAndrew Schrepf
Chronic Pain and Fatigue Research Centre, University of Michigan, Ann Arbor, MI, USA
6 shared publicationsIrene Tracey
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
6 shared publicationsChelsea M. Kaplan
Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, USA
3 shared publicationsDaniel J. Clauw
Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, USA
3 shared publications- Dearbhla Marie Kelly
Wolfson Centre for the Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom; and
3 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (5) , 1329-1335
Minding the gaps: AGREEing to harmonise clinical guidelines to enhance healthcare and the research agenda
- 28 August 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (5) , 1329-1335
Minding the gaps: AGREEing to harmonise clinical guidelines to enhance healthcare and the research agenda
- Open Access
- 9 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (11) , e218031
Acute Kidney Injury and Risk of Adverse Neurocognitive Outcomes
Background and ObjectivesChronic kidney disease is a recognized risk factor for adverse neurocognitive outcomes, but the effect of acute kidney injury (AKI) on brain health remains less well define...
- 9 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (11) , e218031
Open AccessAcute Kidney Injury and Risk of Adverse Neurocognitive Outcomes
Background and ObjectivesChronic kidney disease is a recognized risk factor for adverse neurocognitive outcomes, but the effect of acute kidney injury (AKI) on brain health remains less well define...
- 29 April 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 342-343
Association of nociplastic pain with executive function decline in a longitudinal cohort of middle-age adults. Response to on Br J Anaesth 2026; 136: 1663–4
- 29 April 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 342-343
Association of nociplastic pain with executive function decline in a longitudinal cohort of middle-age adults. Response to on Br J Anaesth 2026; 136: 1663–4
- 13 April 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (6) , 1744-1752
What can UK Biobank’s 500 000 participants teach us about chronic pain?
- 13 April 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (6) , 1744-1752
What can UK Biobank’s 500 000 participants teach us about chronic pain?
- Open Access
- 24 March 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (2)
Serum neurofilament light chain in fibromyalgia: comparative evidence of neuronal injury across chronic pain conditions
Introduction: Evidence increasingly shows small nerve fibre pathology in subsets of people with fibromyalgia through skin biopsy, corneal confocal microscopy, and microneurography. However, blood-based biomarkers of ongoing neuronal damage, particularly neurofilament light chain (NfL), an axonal structural protein, are not well established. Objectives: The aim of this study was to evaluate serum NfL concentrations in fibromyalgia compared with other chronic pain conditions and assess their relationship with neuropathic-like pain. Methods: We measured serum NfL using Simoa SR-X NF Light v2 digital-immunoassay in 60 participants with fibromyalgia, 61 with endometriosis (another traditionally considered non-neuropathic pain condition), 24 with small fibre neuropathy (a recognised neuropathic pain condition), and 30 healthy controls. Serum NfL concentrations were compared between the groups controlling for age and body mass index. Neuropathic-like pain was assessed using the painDETECT questionnaire for fibromyalgia and endometriosis and NeuPSIG grading criteria for small fibre neuropathy. Results: Compared with healthy controls (mean concentration = 6.77 pg/mL, Z-score = −1.15), serum NfL concentrations were significantly elevated in fibromyalgia (mean concentration = 8.52 pg/mL P = 0.048; Z-score = −0.30, and P = 0.006) and small fibre neuropathy (mean concentration = 8.98 pg/mL, P = 0.004; Z-score = 0.23, P = 0.0001), with endometriosis representing an intermediate phenotype (mean concentration = 5.57 pg/mL, P = 0.44; Z-score = −0.41, P = 0.024). Using PainDETECT, 44% of fibromyalgia and 26% of endometriosis participants met likely neuropathic pain criteria; using NeupSIG grading, 96% of small fibre neuropathy participants met probable/definite criteria. Conclusion: Our study provides serological evidence of nerve pathology in fibromyalgia at comparable levels with small fibre neuropathy, although this did not correlate with neuropathic-like pain presence or severity. These findings highlight the need for subgroup-specific treatment strategies.
- 24 March 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (2)
Open AccessSerum neurofilament light chain in fibromyalgia: comparative evidence of neuronal injury across chronic pain conditions
Introduction: Evidence increasingly shows small nerve fibre pathology in subsets of people with fibromyalgia through skin biopsy, corneal confocal microscopy, and microneurography. However, blood-based biomarkers of ongoing neuronal damage, particularly neurofilament light chain (NfL), an axonal structural protein, are not well established. Objectives: The aim of this study was to evaluate serum NfL concentrations in fibromyalgia compared with other chronic pain conditions and assess their relationship with neuropathic-like pain. Methods: We measured serum NfL using Simoa SR-X NF Light v2 digital-immunoassay in 60 participants with fibromyalgia, 61 with endometriosis (another traditionally considered non-neuropathic pain condition), 24 with small fibre neuropathy (a recognised neuropathic pain condition), and 30 healthy controls. Serum NfL concentrations were compared between the groups controlling for age and body mass index. Neuropathic-like pain was assessed using the painDETECT questionnaire for fibromyalgia and endometriosis and NeuPSIG grading criteria for small fibre neuropathy. Results: Compared with healthy controls (mean concentration = 6.77 pg/mL, Z-score = −1.15), serum NfL concentrations were significantly elevated in fibromyalgia (mean concentration = 8.52 pg/mL P = 0.048; Z-score = −0.30, and P = 0.006) and small fibre neuropathy (mean concentration = 8.98 pg/mL, P = 0.004; Z-score = 0.23, P = 0.0001), with endometriosis representing an intermediate phenotype (mean concentration = 5.57 pg/mL, P = 0.44; Z-score = −0.41, P = 0.024). Using PainDETECT, 44% of fibromyalgia and 26% of endometriosis participants met likely neuropathic pain criteria; using NeupSIG grading, 96% of small fibre neuropathy participants met probable/definite criteria. Conclusion: Our study provides serological evidence of nerve pathology in fibromyalgia at comparable levels with small fibre neuropathy, although this did not correlate with neuropathic-like pain presence or severity. These findings highlight the need for subgroup-specific treatment strategies.
- Open Access
- 23 March 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (7) , 1603-1614
Neuropathic-like pain characteristics predict worse pain outcomes in early rheumatoid arthritis: a prospective cohort study with embedded neuroimaging evaluation
Despite effective control of inflammation in rheumatoid arthritis (RA), persistent and severe pain remains a challenge. Dysregulated pain processing in the central nervous system may underlie this disconnect. The PainDETECT questionnaire, originally developed to identify neuropathic pain, may capture features of central sensitization. We hypothesized that neuropathic-like pain at diagnosis predicts worse pain prognosis in early RA, independent of baseline pain severity and inflammation. We also explored brain activation patterns using neuroimaging. In this prospective cohort study, adults with newly diagnosed RA completed the PainDETECT questionnaire at baseline. Bodily pain was measured using the SF-36 Bodily Pain Subscale at baseline, 3, 6, and 12 months. C-reactive protein (CRP) was monitored. Linear mixed-effects models examined associations between PainDETECT, as a continuous measure, and bodily pain and CRP over time, adjusting for baseline outcome values. A neuroimaging substudy (n = 27) used task-based functional MRI to assess brain responses to evoked pressure pain. Among 158 participants (mean age 58.4 years; 35% male), 24.7% had likely neuropathic-like pain (PainDETECT ≥19) at baseline. Higher baseline PainDETECT scores were associated with worse bodily pain throughout follow-up in fully adjusted models (β = −0.43; 95% CI: −0.84 to −0.02; P = 0.043), independent of socio-demographics and comorbidities. No association was found between PainDETECT and CRP. On neuroimaging, higher PainDETECT scores correlated with increased activation in the left insula, dorsal anterior cingulate cortex, and left amygdala during evoked wrist pain. Neuropathic-like pain at diagnosis predicts a worse pain prognosis in early RA, independently of inflammation. Early identification may support more targeted and effective pain management.
- 23 March 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (7) , 1603-1614
Open AccessNeuropathic-like pain characteristics predict worse pain outcomes in early rheumatoid arthritis: a prospective cohort study with embedded neuroimaging evaluation
Despite effective control of inflammation in rheumatoid arthritis (RA), persistent and severe pain remains a challenge. Dysregulated pain processing in the central nervous system may underlie this disconnect. The PainDETECT questionnaire, originally developed to identify neuropathic pain, may capture features of central sensitization. We hypothesized that neuropathic-like pain at diagnosis predicts worse pain prognosis in early RA, independent of baseline pain severity and inflammation. We also explored brain activation patterns using neuroimaging. In this prospective cohort study, adults with newly diagnosed RA completed the PainDETECT questionnaire at baseline. Bodily pain was measured using the SF-36 Bodily Pain Subscale at baseline, 3, 6, and 12 months. C-reactive protein (CRP) was monitored. Linear mixed-effects models examined associations between PainDETECT, as a continuous measure, and bodily pain and CRP over time, adjusting for baseline outcome values. A neuroimaging substudy (n = 27) used task-based functional MRI to assess brain responses to evoked pressure pain. Among 158 participants (mean age 58.4 years; 35% male), 24.7% had likely neuropathic-like pain (PainDETECT ≥19) at baseline. Higher baseline PainDETECT scores were associated with worse bodily pain throughout follow-up in fully adjusted models (β = −0.43; 95% CI: −0.84 to −0.02; P = 0.043), independent of socio-demographics and comorbidities. No association was found between PainDETECT and CRP. On neuroimaging, higher PainDETECT scores correlated with increased activation in the left insula, dorsal anterior cingulate cortex, and left amygdala during evoked wrist pain. Neuropathic-like pain at diagnosis predicts a worse pain prognosis in early RA, independently of inflammation. Early identification may support more targeted and effective pain management.
- Top Cited PapersOpen Access
- 17 February 2026
- Published by Elsevier in EBioMedicine
- Vol. 125, 106158
Why sleep matters in chronic pain: evidence across the lifespan
- 17 February 2026
- Published by Elsevier in EBioMedicine
- Vol. 125, 106158
Top Cited PapersOpen AccessWhy sleep matters in chronic pain: evidence across the lifespan
- 9 February 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (5) , 1413-1417
Beyond traditional publishing: the British Journal of Anaesthesia and social media in anaesthesia research
- 9 February 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (5) , 1413-1417
Beyond traditional publishing: the British Journal of Anaesthesia and social media in anaesthesia research
- Open Access
- 14 November 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (1) , 3-14
Beyond Inflammation: Why Understanding the Brain Matters in Inflammatory Arthritis
Persistent pain remains a major challenge in inflammatory arthritis, even when joint inflammation is well controlled. Pain and associated symptoms such as fatigue cannot be explained by peripheral inflammation alone but reflect altered central pain processing. These changes may arise through “top‐down” mechanisms, reflecting pre‐existing dysfunction in pain perception, or “bottom‐up” pathways, driven by peripheral inflammation acting on the brain. Neuroimaging has transformed understanding of these processes by providing in vivo markers of how brain function and structure are related to pain. Functional magnetic resonance imaging (MRI) demonstrates that both task‐evoked and resting‐state activity are altered in inflammatory arthritis. Connectivity changes involving the thalamus, insula, medial prefrontal cortex, and default mode and salience networks correlate with pain, fatigue, and affective symptoms. Notably, tumor necrosis factor α (TNF‐α) inhibitors rapidly normalize pain‐related activation, preceding improvements in joint swelling, strongly supporting a bottom‐up role for peripheral inflammation. Recent randomized controlled trial data show that baseline central nervous system pain activation predicts analgesic response to TNF‐α blockade, positioning neuroimaging as a potential tool for treatment stratification. Complementary modalities provide further insights. Proton electron tomography studies suggest altered pain responses, and novel tracers may clarify contributions of neuroinflammation. Magnetic resonance spectroscopy reveals neurochemical correlates such as increased choline and myo‐inositol linked to fatigue, although group‐level evidence for overt neuroinflammation remains limited. Structural MRI highlights gray matter changes in regions mediating sensory, cognitive, and affective processing. Together, this supports a dual top‐down and bottom‐up model of persistent pain in inflammatory arthritis, with important implications for mechanism‐based therapies targeting both immune and brain pathways. image
- 14 November 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (1) , 3-14
Open AccessBeyond Inflammation: Why Understanding the Brain Matters in Inflammatory Arthritis
Persistent pain remains a major challenge in inflammatory arthritis, even when joint inflammation is well controlled. Pain and associated symptoms such as fatigue cannot be explained by peripheral inflammation alone but reflect altered central pain processing. These changes may arise through “top‐down” mechanisms, reflecting pre‐existing dysfunction in pain perception, or “bottom‐up” pathways, driven by peripheral inflammation acting on the brain. Neuroimaging has transformed understanding of these processes by providing in vivo markers of how brain function and structure are related to pain. Functional magnetic resonance imaging (MRI) demonstrates that both task‐evoked and resting‐state activity are altered in inflammatory arthritis. Connectivity changes involving the thalamus, insula, medial prefrontal cortex, and default mode and salience networks correlate with pain, fatigue, and affective symptoms. Notably, tumor necrosis factor α (TNF‐α) inhibitors rapidly normalize pain‐related activation, preceding improvements in joint swelling, strongly supporting a bottom‐up role for peripheral inflammation. Recent randomized controlled trial data show that baseline central nervous system pain activation predicts analgesic response to TNF‐α blockade, positioning neuroimaging as a potential tool for treatment stratification. Complementary modalities provide further insights. Proton electron tomography studies suggest altered pain responses, and novel tracers may clarify contributions of neuroinflammation. Magnetic resonance spectroscopy reveals neurochemical correlates such as increased choline and myo‐inositol linked to fatigue, although group‐level evidence for overt neuroinflammation remains limited. Structural MRI highlights gray matter changes in regions mediating sensory, cognitive, and affective processing. Together, this supports a dual top‐down and bottom‐up model of persistent pain in inflammatory arthritis, with important implications for mechanism‐based therapies targeting both immune and brain pathways. image
- 28 October 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (1) , 377-379
From association to action: why causal estimands matter in perioperative studies of glucagon-like peptide-1 receptor agonist outcomes
- 28 October 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (1) , 377-379
From association to action: why causal estimands matter in perioperative studies of glucagon-like peptide-1 receptor agonist outcomes